Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2003 Nov 15;376(Pt 1):285–290. doi: 10.1042/BJ20030821

Differential modulation of glucocorticoid action by FK506 in A549 cells.

Jamie D Croxtall 1, Mark Paul-Clark 1, Peter Th W Van Hal 1
PMCID: PMC1223764  PMID: 12948397

Abstract

Glucocorticoids inhibit the release of eicosanoid pro-inflammatory mediators. The immunosuppressant FK506 is known to enhance many aspects of glucocorticoid action. In the present study we show that FK506 (1 microM or 10 microM) inhibits the release of arachidonic acid and prostaglandin E2 from A549 cells and also inhibits their proliferation. Simultaneous treatment of FK506 together with the glucocorticoids dexamethasone, methyl-prednisolone, fluticasone or mometasone (10 nM) enhances the growth inhibitory effect of these steroids. Furthermore, the simultaneous use of FK506 and these glucocorticoids similarly results in enhanced inhibition of arachidonic acid release. When pretreated for 2 h, FK506 enhances glucocorticoid inhibition of COX2 (cyclo-oxygenase 2) expression. However, when administered simultaneously, FK506 blocks glucocorticoid inhibition of COX2 expression. Nuclear uptake of glucocorticoid receptors mediated by glucocorticoids is also blocked by the simultaneous administration of FK506. These results suggest that the effect of simultaneous treatment of FK506 with glucocorticoids differs significantly from that where pre-treatment of the immunosuppressant is used. Recently, immunophilin interchange has been identified as a first step in glucocorticoid receptor activation following ligand activation. We show here that the FKB51 (FK506-binding protein 51)-FKB52 switch is differentially regulated by glucocorticoid and FK506 treatment strategy.

Full Text

The Full Text of this article is available as a PDF (146.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P. J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002 Jan;19(1):182–191. doi: 10.1183/09031936.02.00283202. [DOI] [PubMed] [Google Scholar]
  2. Croxtall J. D., Choudhury Q., Flower R. J. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol. 2000 May;130(2):289–298. doi: 10.1038/sj.bjp.0703272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Croxtall J. D., Flower R. J. Lipocortin 1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3571–3575. doi: 10.1073/pnas.89.8.3571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Croxtall Jamie D., van Hal Peter Th W., Choudhury Qam, Gilroy Derek W., Flower Rod J. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol. 2002 Jan;135(2):511–519. doi: 10.1038/sj.bjp.0704474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davies Todd H., Ning Yang-Min, Sánchez Edwin R. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem. 2001 Dec 20;277(7):4597–4600. doi: 10.1074/jbc.C100531200. [DOI] [PubMed] [Google Scholar]
  6. Gustafsson J. A., Carlstedt-Duke J., Poellinger L., Okret S., Wikström A. C., Brönnegård M., Gillner M., Dong Y., Fuxe K., Cintra A. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev. 1987 May;8(2):185–234. doi: 10.1210/edrv-8-2-185. [DOI] [PubMed] [Google Scholar]
  7. Hasan Q., Tan S. T., Xu B., Davis P. F. Effects of five commonly used glucocorticoids on haemangioma in vitro. Clin Exp Pharmacol Physiol. 2003 Mar;30(3):140–144. doi: 10.1046/j.1440-1681.2003.03815.x. [DOI] [PubMed] [Google Scholar]
  8. Hurwitz C. A., Silverman L. B., Schorin M. A., Clavell L. A., Dalton V. K., Glick K. M., Gelber R. D., Sallan S. E. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000 Apr 15;88(8):1964–1969. [PubMed] [Google Scholar]
  9. Marchetti Maria Cristina, Di Marco Barbara, Cifone Grazia, Migliorati Graziella, Riccardi Carlo. Dexamethasone-induced apoptosis of thymocytes: role of glucocorticoid receptor-associated Src kinase and caspase-8 activation. Blood. 2002 Aug 29;101(2):585–593. doi: 10.1182/blood-2002-06-1779. [DOI] [PubMed] [Google Scholar]
  10. Marsaud V., Mercier-Bodard C., Fortin D., Le Bihan S., Renoir J. M. Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands. J Steroid Biochem Mol Biol. 1998 Jul;66(1-2):11–25. doi: 10.1016/s0960-0760(98)00008-9. [DOI] [PubMed] [Google Scholar]
  11. Migita K., Tanaka H., Okamoto K., Yoshikawa N., Ichinose Y., Urayama S., Yamasaki S., Ida H., Kawabe Y., Kawakami A. FK506 augments glucocorticoid-mediated cyclooxygenase-2 down-regulation in human rheumatoid synovial fibroblasts. Lab Invest. 2000 Feb;80(2):135–141. doi: 10.1038/labinvest.3780017. [DOI] [PubMed] [Google Scholar]
  12. Mursch K., Buhre W., Behnke-Mursch J., Markakis E. Peroperative cardiovascular stability during brainstem surgery. The use of high-dose methylprednisolone compared to dexamethasone. A retrospective analysis. Acta Anaesthesiol Scand. 2000 Apr;44(4):378–382. doi: 10.1034/j.1399-6576.2000.440404.x. [DOI] [PubMed] [Google Scholar]
  13. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000 Jul;55(7):603–613. doi: 10.1136/thorax.55.7.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ning Y. M., Sánchez E. R. Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin. J Biol Chem. 1993 Mar 25;268(9):6073–6076. [PubMed] [Google Scholar]
  15. Pratt W. B., Silverstein A. M., Galigniana M. D. A model for the cytoplasmic trafficking of signalling proteins involving the hsp90-binding immunophilins and p50cdc37. Cell Signal. 1999 Dec;11(12):839–851. doi: 10.1016/s0898-6568(99)00064-9. [DOI] [PubMed] [Google Scholar]
  16. Riggs Daniel L., Roberts Patricia J., Chirillo Samantha C., Cheung-Flynn Joyce, Prapapanich Viravan, Ratajczak Thomas, Gaber Richard, Picard Didier, Smith David F. The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J. 2003 Mar 3;22(5):1158–1167. doi: 10.1093/emboj/cdg108. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES